Characterizing the evolution of Subjective Cognitive Decline in preclinical Alzheimer's disease

表征临床前阿尔茨海默病主观认知衰退的演变

• 批准号: 10532669
• 负责人: Rebecca E Amariglio
• 金额: $ 75.96万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-01 至 2024-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10532669
• 关键词: Age; Alzheimer disease prevention; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer’s disease biomarker; Amyloid; Amyloid beta-Protein; Anxiety; Biological Markers; Cellular Phone; Clinic; Clinical; Cognitive; Communities; Complement; Computers; Cross-Sectional Studies; Demographic Impact; Disease Marker; Disease Progression; Early Diagnosis; Education; Elderly; Electronics; Episodic memory; Etiology; Evolution; Frequencies; Genetic; Glean; Goals; Hippocampus; Home; Impaired cognition; Individual; Inferior; Investigation; Knowledge; Magnetic Resonance Imaging; Measures; Memory; Memory Disorders; Methods; Modeling; Moods; National Institute on Alcohol Abuse and Alcoholism; Nerve Degeneration; Neurobehavioral Manifestations; Neuropsychological Tests; Neuropsychology; Participant; Patient Self-Report; Pattern; Performance; Persons; Phase; Pittsburgh Compound-B; Positron-Emission Tomography; Prevention; Prevention trial; Questionnaires; Reporting; Research; Self Assessment; Severities; Severity of illness; Source; Standardization; Symptoms; Tablets; Temporal Lobe; Time; White Matter Hyperintensity; aging brain; amyloid imaging; associated symptom; autosomal dominant Alzheimer' s disease; carrier status; clinical diagnosis; clinical predictors; cognitive function; cognitive performance; cognitive testing; cohort; common symptom; direct application; entorhinal cortex; executive function; high risk; improved; in vivo; novel strategies; pre-clinical; recruit; risk prediction; sex; tau Proteins; tau aggregation; treatment effect; treatment response; treatment strategy

Project Summary As Alzheimer's disease (AD) treatment strategies increasingly focus on prevention at the preclinical stage, a corresponding effort to improve detection of early changes in cognitive function is urgently needed. Subjective Cognitive Decline (SCD) provides a unique opportunity to identify emerging cognitive symptoms from the person's own perspective that can complement neuropsychological assessment at the preclinical stage. Furthermore, SCD has direct applications for AD prevention trials seeking to demonstrate treatment effects that impact study participants' daily lives. We propose to recruit a new cohort of SCD individuals who report a concern for recent, persistent changes in cognitive functioning. Individuals will be recruited from both the community and the memory disorders clinics (n=100) and will be followed over the course of 3 years. Specifically, we will capture high frequency SCD report (i.e., quarterly) that can be administered unsupervised via personal electronic device (e.g., computer, smart phone, tablet). In this way, participants will be able to complete assessments at-home, rather than coming to the clinic. SCD trajectories will be associated with other markers of disease severity, including in vivo AD biomarkers longitudinally, amyloid (Pittsburgh Compound B- PET) and tau (Flortaucipir-PET) and objective cognitive decline. The information gleaned from these complementary methods will improve our ability to identify high risk participants more likely to decline and to track clinically meaningful response to treatment.

项目摘要 随着阿尔茨海默病（AD）治疗策略越来越多地关注临床前阶段的预防， 迫切需要相应的努力来改善认知功能早期变化的检测。主观 认知衰退（SCD）提供了一个独特的机会，以确定新兴的认知症状， 人自己的观点，可以补充在临床前阶段的神经心理学评估。 此外，SCD可直接应用于AD预防试验，以证明治疗效果 影响研究参与者的日常生活。我们建议招募一批新的SCD患者，他们报告 关注认知功能最近的持续变化。个人将从两个招聘 社区和记忆障碍诊所（n=100），并将随访3年。 具体而言，我们将捕获高频SCD报告（即，季度），可以在无人监督的情况下进行管理 经由个人电子设备（例如，计算机、智能手机、平板电脑）。通过这种方式，参与者将能够 在家里完成评估，而不是去诊所。SCD轨迹将与其他 疾病严重程度的标志物，包括体内AD生物标志物纵向、淀粉样蛋白（匹兹堡化合物B- PET）和tau（Flortaucipir-PET）和客观认知下降。从这些收集到的信息 补充方法将提高我们识别更有可能衰退的高风险参与者并 跟踪对治疗有临床意义的反应。